Tai Sandi See - Feb 5, 2024 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Development Officer
Signature: /s/ Jenny Robertson, attorney-in-fact
Stock symbol: LXEO
Transactions as of: Feb 5, 2024
Transactions value $: $0
Form type: 3
Date filed: 2/6/2024, 05:58 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LXEO	Common Stock						16.6K	Feb 5, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LXEO	Employee Stock Option (right to buy)							Feb 5, 2024	Common Stock	64.2K	$12.72	Direct	F2
holding	LXEO	Employee Stock Option (right to buy)							Feb 5, 2024	Common Stock	30K	$14.48	Direct	F3
holding	LXEO	Employee Stock Option (right to buy)							Feb 5, 2024	Common Stock	69.8K	$17.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2	25% of the shares underlying the option vest and become exercisable on October 30, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3	25% of the shares underlying the option vest and become exercisable on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F4	25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.